Literature DB >> 25413851

siRNA nanoparticles: the future of RNAi therapeutics for oncology?

Szu-Ting Chou1, A James Mixson.   

Abstract

Entities:  

Keywords:  cancer; gene delivery; nanoparticle; nonviral carrier; siRNA; targeted therapy

Mesh：

Substances：

Year:  2014        PMID： 25413851      PMCID： PMC4788000          DOI： 10.2217/nnm.14.157

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN： 1743-5889            Impact factor:   5.307


× No keyword cloud information.
  23 in total

1.  Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.

Authors:  S-T Chou; Q Leng; P Scaria; M Woodle; A J Mixson
Journal:  Cancer Gene Ther       Date:  2011-08-05       Impact factor: 5.987

2.  Lipid-like materials for low-dose, in vivo gene silencing.

Authors:  Kevin T Love; Kerry P Mahon; Christopher G Levins; Kathryn A Whitehead; William Querbes; J Robert Dorkin; June Qin; William Cantley; Liu Liang Qin; Timothy Racie; Maria Frank-Kamenetsky; Ka Ning Yip; Rene Alvarez; Dinah W Y Sah; Antonin de Fougerolles; Kevin Fitzgerald; Victor Koteliansky; Akin Akinc; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

3.  A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

Authors:  Kazuya Nakamura; Amr S Abu Lila; Mariko Matsunaga; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

4.  Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.

Authors:  Yan-dan Yao; Tian-meng Sun; Song-yin Huang; Shuang Dou; Ling Lin; Jia-ning Chen; Jian-bin Ruan; Cheng-qiong Mao; Feng-yan Yu; Mu-sheng Zeng; Jian-ye Zang; Qiang Liu; Feng-xi Su; Peter Zhang; Judy Lieberman; Jun Wang; Erwei Song
Journal:  Sci Transl Med       Date:  2012-04-18       Impact factor: 17.956

5.  FRET-labeled siRNA probes for tracking assembly and disassembly of siRNA nanocomplexes.

Authors:  Christopher A Alabi; Kevin T Love; Gaurav Sahay; Tina Stutzman; Whitney T Young; Robert Langer; Daniel G Anderson
Journal:  ACS Nano       Date:  2012-06-22       Impact factor: 15.881

6.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Authors:  Charles N Landen; Arturo Chavez-Reyes; Corazon Bucana; Rosemarie Schmandt; Michael T Deavers; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

7.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

8.  Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.

Authors:  Alexey Berezhnoy; Iris Castro; Agata Levay; Thomas R Malek; Eli Gilboa
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

9.  Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds.

Authors:  Szu-Ting Chou; Kellie Hom; Daoning Zhang; Qixin Leng; Lucas J Tricoli; Jason M Hustedt; Amy Lee; Michael J Shapiro; Joonil Seog; Jason D Kahn; A James Mixson
Journal:  Biomaterials       Date:  2013-10-22       Impact factor: 12.479

10.  Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

Authors:  Xiaoyang Xu; Kun Xie; Xue-Qing Zhang; Eric M Pridgen; Ga Young Park; Danica S Cui; Jinjun Shi; Jun Wu; Philip W Kantoff; Stephen J Lippard; Robert Langer; Graham C Walker; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205
View more
  1 in total

1.  Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles.

Authors:  Shoshy Mizrahy; Inbal Hazan-Halevy; Dalit Landesman-Milo; Brandon D Ng; Dan Peer
Journal:  Front Immunol       Date:  2017-02-06       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.